Cosyntropin vs DPDPE
Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and DPDPE ([D-Pen2, D-Pen5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cosyntropin | DPDPE |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Cosyntropin (ACTH 1-24) | [D-Pen2, D-Pen5]-enkephalin |
| Molecular Weight | 2933.3 Da | 645.79 Da |
| Half-Life | ~10 min | 15-60 minutes in plasma |
| Amino Acids | 24 | 5 |
| Typical Dose | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary | 0.01-1 ug per animal |
| Route | IV|IM | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 61 | 800 |
| Research Status | Clinical research | Pre-clinical |
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
DPDPE Benefits
- ✓delta-opioid selectivity
- ✓improved conformational stability
- ✓analgesic receptor mapping
- ✓useful in chronic pain models
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
DPDPE Dosing
Intrathecal 0.01-1 ug per animal|Intracerebroventricular 0.01-0.5 ug per animal|In vitro 0.1-20 nM
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
DPDPE Side Effects
- ⚠sedation
- ⚠nausea-like opioid effects
- ⚠tolerance with repeated dosing
Research Overview
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
DPDPE
DPDPE is widely cited in opioid pharmacology because it helped establish the functional role of delta-opioid receptors in pain control. Its constrained structure is also used to explore how peptide cyclization changes potency, stability, and tissue selectivity.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.